使用敲除细胞株进行验证

Anti-MSH2抗体[25D12] (ab2353)

概述

  • 产品名称Anti-MSH2抗体[25D12]
    参阅全部 MSH2 一抗
  • 描述
    小鼠单克隆抗体[25D12] to MSH2
  • 特异性This antibody reacts with a 102 kD protein known as MSH2 (Mismatch Repair protein 2).
  • 经测试应用适用于: IHC-Fr, IHC-P, WBmore details
  • 种属反应性
    与反应: Human
  • 免疫原

    Recombinant full length protein (Human).

  • 阳性对照
    • Tonsil.

性能

相关产品

应用

Our Abpromise guarantee covers the use of ab2353 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

应用 Ab评论 说明
IHC-Fr Use at an assay dependent concentration.
IHC-P Use at an assay dependent concentration.
WB 1/500. Detects a band of approximately 105 kDa (predicted molecular weight: 105 kDa).

靶标

  • 功能Component of the post-replicative DNA mismatch repair system (MMR). Forms two different heterodimers: MutS alpha (MSH2-MSH6 heterodimer) and MutS beta (MSH2-MSH3 heterodimer) which binds to DNA mismatches thereby initiating DNA repair. When bound, heterodimers bend the DNA helix and shields approximately 20 base pairs. MutS alpha recognizes single base mismatches and dinucleotide insertion-deletion loops (IDL) in the DNA. MutS beta recognizes larger insertion-deletion loops up to 13 nucleotides long. After mismatch binding, MutS alpha or beta forms a ternary complex with the MutL alpha heterodimer, which is thought to be responsible for directing the downstream MMR events, including strand discrimination, excision, and resynthesis. ATP binding and hydrolysis play a pivotal role in mismatch repair functions. The ATPase activity associated with MutS alpha regulates binding similar to a molecular switch: mismatched DNA provokes ADP-->ATP exchange, resulting in a discernible conformational transition that converts MutS alpha into a sliding clamp capable of hydrolysis-independent diffusion along the DNA backbone. This transition is crucial for mismatch repair. MutS alpha may also play a role in DNA homologous recombination repair. In melanocytes may modulate both UV-B-induced cell cycle regulation and apoptosis.
  • 组织特异性Ubiquitously expressed.
  • 疾病相关Defects in MSH2 are the cause of hereditary non-polyposis colorectal cancer type 1 (HNPCC1) [MIM:120435]. Mutations in more than one gene locus can be involved alone or in combination in the production of the HNPCC phenotype (also called Lynch syndrome). Most families with clinically recognized HNPCC have mutations in either MLH1 or MSH2 genes. HNPCC is an autosomal, dominantly inherited disease associated with marked increase in cancer susceptibility. It is characterized by a familial predisposition to early onset colorectal carcinoma (CRC) and extra-colonic cancers of the gastrointestinal, urological and female reproductive tracts. HNPCC is reported to be the most common form of inherited colorectal cancer in the Western world. Cancers in HNPCC originate within benign neoplastic polyps termed adenomas. Clinically, HNPCC is often divided into two subgroups. Type I: hereditary predisposition to colorectal cancer, a young age of onset, and carcinoma observed in the proximal colon. Type II: patients have an increased risk for cancers in certain tissues such as the uterus, ovary, breast, stomach, small intestine, skin, and larynx in addition to the colon. Diagnosis of classical HNPCC is based on the Amsterdam criteria: 3 or more relatives affected by colorectal cancer, one a first degree relative of the other two; 2 or more generation affected; 1 or more colorectal cancers presenting before 50 years of age; exclusion of hereditary polyposis syndromes. The term "suspected HNPCC" or "incomplete HNPCC" can be used to describe families who do not or only partially fulfill the Amsterdam criteria, but in whom a genetic basis for colon cancer is strongly suspected. MSH2 mutations may predispose to hematological malignancies and multiple cafe-au-lait spots.
    Defects in MSH2 are a cause of Muir-Torre syndrome (MuToS) [MIM:158320]; also abbreviated MTS. MuToS is a rare autosomal dominant disorder characterized by sebaceous neoplasms and visceral malignancy.
    Defects in MSH2 are a cause of susceptibility to endometrial cancer (ENDMC) [MIM:608089].
    Defects in MSH2 are a cause of hereditary non-polyposis colorectal cancer type 8 (HNPCC8) [MIM:613244]. HNPCC is a disease associated with marked increase in cancer susceptibility. It is characterized by a familial predisposition to early-onset colorectal carcinoma (CRC) and extra-colonic tumors of the gastrointestinal, urological and female reproductive tracts. HNPCC is reported to be the most common form of inherited colorectal cancer in the Western world. Clinically, HNPCC is often divided into two subgroups. Type I is characterized by hereditary predisposition to colorectal cancer, a young age of onset, and carcinoma observed in the proximal colon. Type II is characterized by increased risk for cancers in certain tissues such as the uterus, ovary, breast, stomach, small intestine, skin, and larynx in addition to the colon. Diagnosis of classical HNPCC is based on the Amsterdam criteria: 3 or more relatives affected by colorectal cancer, one a first degree relative of the other two; 2 or more generation affected; 1 or more colorectal cancers presenting before 50 years of age; exclusion of hereditary polyposis syndromes. The term 'suspected HNPCC' or 'incomplete HNPCC' can be used to describe families who do not or only partially fulfill the Amsterdam criteria, but in whom a genetic basis for colon cancer is strongly suspected. Note=HNPCC8 results from heterozygous deletion of 3-prime exons of EPCAM and intergenic regions directly upstream of MSH2, resulting in transcriptional read-through and epigenetic silencing of MSH2 in tissues expressing EPCAM.
  • 序列相似性Belongs to the DNA mismatch repair mutS family.
  • 翻译后修饰Phosphorylated by PRKCZ, which may prevent MutS alpha degradation by the ubiquitin-proteasome pathway.
    Phosphorylated upon DNA damage, probably by ATM or ATR.
  • 细胞定位Nucleus.
  • Information by UniProt
  • 数据库链接
  • 别名
    • BAT26 antibody
    • COCA 1 antibody
    • COCA1 antibody
    • DNA mismatch repair protein Msh2 antibody
    • FCC 1 antibody
    • FCC1 antibody
    • hMSH2 antibody
    • HNPCC 1 antibody
    • HNPCC antibody
    • HNPCC1 antibody
    • LCFS2 antibody
    • MSH 2 antibody
    • Msh2 antibody
    • MSH2_HUMAN antibody
    • MutS homolog 2 antibody
    • MutS homolog 2 colon cancer nonpolyposis type 1 antibody
    • MutS protein homolog 2 antibody
    see all

Anti-MSH2 antibody [25D12] 图像



  • Predicted band size : 105 kDa

    Lane 1: Wild-type HAP1 cell lysate (20 µg)
    Lane 2: MSH2 knockout HAP1 cell lysate (20 µg)
    Lane 3: HeLa cell lysate (20 µg)
    Lane 4: A375 cell lysate (20 µg)
    Lanes 1 - 4: Merged signal (red and green). Green - ab2353 observed at 115 kDa. Red - loading control, ab181602, observed at 37 kDa.
    ab2353 was shown to specifically react with MSH2 when MSH2 knockout samples were used. Wild-type and MSH2 knockout samples were subjected to SDS-PAGE. ab2353 and ab181602 (loading control to GAPDH) were diluted 1/500 and 1/2000 respectively and incubated overnight at 4°C. Blots were developed with goat anti-rabbit IgG (H + L) and goat anti-mouse IgG (H + L) secondary antibodies at 1/10 000 dilution for 1 h at room temperature before imaging.

  • Anti-MSH2 antibody [25D12] (ab2353) at 1/500 dilution + JEG-3 (Human placental choriocarcinoma cell line) Whole Cell Lysate at 10 µg

    Secondary
    Goat polyclonal to Mouse IgG - H&L - Pre-Adsorbed (HRP) at 1/3000 dilution

    Predicted band size : 105 kDa
    Observed band size : 105 kDa
  • Immunohistochemical analysis of formalin-fixed, paraffin-embedded Human tonsil tissue, staining MSH2 with ab2353.

Anti-MSH2 antibody [25D12] (ab2353)参考文献

ab2353 has not yet been referenced specifically in any publications.

Product Wall

There are currently no Abreviews or Questions for ab2353.
Please use the links above to contact us or submit feedback about this product.

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"